HOME >> MEDICINE >> NEWS
New study suggests that tamoxifen does not adversely impact brain chemistry

Torrance, Calif. (April 11, 2002) Surprising results from a new study may quell concerns about the safety of using tamoxifen to reduce breast cancer risk in elderly women, suggesting that both tamoxifen and estrogen have similar effects on the brain. The study was conducted at Harbor-UCLA Research & Education Institute (REI) in Torrance, California by research collaborators Rowan Chlebowski, M.D., Ph.D. and Thomas Ernst, Ph.D. and Linda Chang, M.D., of Brookhaven National Laboratory in New York. The findings will be published in the April 17 issue of the Journal of the National Cancer Institute and promise to advance breast cancer risk reduction as an achievable medical objective in the near future.

Based on the increase in hot flashes that are associated with tamoxifen, it has been suggested that the drug blocks the potentially favorable effects of estrogen on the brain. Weve found just the opposite, said Dr. Chlebowski. We were surprised to find similarities between the two groups in that women who have been treated with tamoxifen had lower levels of myo-inositol, a chemical that increases in response to brain injury. Women who took estrogen also had lower levels of the chemical, he added.

This study is unique in that it uses Proton Magnetic Resonance Spectroscopy (MRS), a non-radioactive brain imaging technique to measure levels of cerebral metabolites in this case myo-inositol to predict the effects of tamoxifen. The study compared levels of myo-inositol in 16 breast cancer survivors who had been treated with tamoxifen for at least two years, 27 healthy women who had been treated with preventive estrogen replacement therapy for at least two years, and 33 healthy women who had not received any treatment.

Study participants were between the ages of 65 and 80 who did not have any neurologic diseases. Dr. Chlebowski and his collaborators concluded that both tamoxifen and estrogen may be neuroprotective and may have favorable
'"/>

Contact: Barbara Kerr
bkerr@rei.edu
310-222-2820
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
16-Apr-2002


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology:
Cached News: